The Abraaj Group partially exits its stake in Unimed, a leading pharmaceutical company in Tunisia

Abraaj Group announced the successful exit through one of its Funds of a partial stake in leading Tunisian pharmaceutical company Unité de fabrication de médicaments.

22 December 2015
· Abraaj and Proparco divest 83% of their combined stake to a consortium of investors

· Partial exit is a first step towards listing the company in H1 2016 on the Tunis stock exchange

Tunis, Tunisia: The Abraaj Group ('Abraaj' or the 'Group'), a leading investor operating in global growth markets, today announced the successful exit through one of its Funds of a partial stake in leading Tunisian pharmaceutical company Unité de fabrication de médicaments ('Unimed' or the 'Company'). Abraaj and development finance institution Société de Promotion et de Participation pour la Coopération Economique S.A. ('Proparco')exited 83% of their combined stake to a consortium of investors including Washington-based SQM, Blakeney Asset Management, the Tunisian-Kuwaiti Consortium of Development (CTKD), and two local investors.

Established in 1989 by Ridha Charfeddine, Unimed is the second largest local pharmaceutical company in Tunisia, specializing in sterile dosage forms such as liquid and powder injectables, intravenous (IV) solutions and a range of ophthalmic products. Unimed manufactures for global partners such as Pfizer and Mylan, and is the first company in Tunisia to be AFFSAP-certified.

Abraaj, through one of its Funds, invested in Unimed in 2011. Since the start of its investment, Abraaj, alongside Unimed's leadership team, increased the Company's revenue year-on-year. Unimed currently holds 329 marketing authorizations, including 97 obtained over the last two years. The Company has also increasingly adopted an export-focused strategy which resulted in 41.5% of total sales in 2014 being exported to over 17 countries in North Africa, West Africa, Europe and the Middle East.

Abraaj's financial and operational support has enabled Unimed to expand its regional footprint, upgrade manufacturing equipment and enhance its corporate governance and financial reporting mechanisms. Unimed places a strong focus on workforce development by implementing training and development programs for its employees. Almost half of Unimed's workforce is made up of women, 25.8% higher than the average female to male ratio in the Tunisian labor force.

Ahmed Badreldin, Partner and Regional Head for Middle East and North Africa at The Abraaj Group, said: "Our investment in Unimed over the past four years has helped cement the company's position as a leading pharmaceutical manufacturer in North Africa. The healthcare market, a critical sector in North Africa, is still underserved and growing rapidly, driven by a rising middle class with an increasing propensity to invest in quality healthcare. We believe Unimed is now well positioned to capitalize on the substantial growth opportunities that it will have as a listed company on the Tunis stock exchange and as it expands across the African continent and the wider Middle East region."

Adel Goucha, Managing Director at The Abraaj Group, added: "With a focus on increasing manufacturing capacity and acquiring the latest production technologies, enhancing R&D capabilities and expanding their export footprint, Unimed has achieved strong, sustainable growth and is now recognized regionally as a leader in injectables. Alongside our new and existing partners, we look forward to supporting Unimed's continued success as it seeks to pursue further expansion opportunities."

Commenting on the transaction, Ridha Charfeddine, Founder at Unimed, said: "Abraaj has played an instrumental role in helping us provide trusted healthcare solutions across North Africa and increase our exports to regional markets. With our new partners on board, we look forward to working together in the next growth chapter of our business."

Since 2003, Abraaj has deployed nearly US$ 1 billion globally across the healthcare spectrum in growth markets, including healthcare delivery and services, diagnostics centers and pharmaceuticals. Abraaj has four investments in Tunisia including the North Africa Hospital Holdings Group, a healthcare platform to enhance the quality and accessibility of healthcare in Egypt and Tunisia, and L'Accumulateur Tunisien ASSAD, a leading battery manufacturer.

Stay connected:  @abraajgroup

For more information please contact:
Mitali Atal
Director - Communications
The Abraaj Group
: + 971 50 8503587
Grace Chaoui
: +971 55 6329593
The Abraaj Group ("Abraaj" or "the Group") is a leading private equity investor, purpose-built for operating in the growth markets of Africa, Asia, Latin America, the Middle East, and Turkey.

Employing over 300 people, Abraaj has over 20 offices spread across five regions with hubs in Dubai, Istanbul, Mexico City, Nairobi and Singapore. The Group currently manages c. US$ 9 billion across regional, sector and country-specific Funds.

Abraaj has realized c. US$ 5.4 billion from 80 full and partial exits, and Funds managed by the Group have made over 140 investments across a range of sectors including consumer, energy, financials, healthcare and utilities. The Group is committed to the highest environmental, stakeholder engagement and corporate governance standards and is a signatory to the United Nations-backed Principles for Responsible Investment and the United Nations Global Compact. Abraaj's founder, Arif Naqvi, was appointed to the United Nations Global Compact Board by UN Secretary-General Ban Ki-moon in 2012 and to the Interpol Foundation Board in 2014.

This publication is issued by Abraaj Capital Limited ("ACLD" or the "Firm"), a member of The Abraaj Group that is authorized and regulated by the Dubai Financial Services Authority ("DFSA"). Several Group members are regulated by a number of international regulatory authorities including the DFSA under whose rules ACLD has issued this publication.

© Press Release 2015

More From Press Releases